213 related articles for article (PubMed ID: 36999373)
1. Targeting CD20 in multiple sclerosis - review of current treatment strategies.
Chmielewska N; Szyndler J
Neurol Neurochir Pol; 2023; 57(3):235-242. PubMed ID: 36999373
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
[TBL] [Abstract][Full Text] [Related]
3. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
Frisch ES; Pretzsch R; Weber MS
Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
Cotchett KR; Dittel BN; Obeidat AZ
Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
Margoni M; Preziosa P; Filippi M; Rocca MA
J Neurol; 2022 Mar; 269(3):1316-1334. PubMed ID: 34382120
[TBL] [Abstract][Full Text] [Related]
6. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
Ancau M; Berthele A; Hemmer B
Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
[TBL] [Abstract][Full Text] [Related]
7. B-Cell-Directed Therapies: A New Era in Multiple Sclerosis Treatment.
Kanatas P; Stouras I; Stefanis L; Stathopoulos P
Can J Neurol Sci; 2023 May; 50(3):355-364. PubMed ID: 35570581
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
Kaegi C; Wuest B; Crowley C; Boyman O
Front Immunol; 2021; 12():788830. PubMed ID: 35185862
[TBL] [Abstract][Full Text] [Related]
9. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
10. Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.
Boldrini VO; Mader S; Kümpfel T; Meinl E
Mult Scler Relat Disord; 2023 Jul; 75():104733. PubMed ID: 37156035
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab and Other CD20
Gelfand JM; Cree BAC; Hauser SL
Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
[TBL] [Abstract][Full Text] [Related]
12. Therapies for multiple sclerosis targeting B cells.
Milo R
Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
Sellebjerg F; Blinkenberg M; Sorensen PS
CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
[TBL] [Abstract][Full Text] [Related]
14. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.
Carlson AK; Amin M; Cohen JA
Drugs; 2024 Mar; 84(3):285-304. PubMed ID: 38480630
[TBL] [Abstract][Full Text] [Related]
15. B cell-directed therapies in multiple sclerosis.
Gasperi C; Stüve O; Hemmer B
Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
[TBL] [Abstract][Full Text] [Related]
16. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives.
D'Amico E; Zanghì A; Gastaldi M; Patti F; Zappia M; Franciotta D
Autoimmun Rev; 2019 Jul; 18(7):665-672. PubMed ID: 31059839
[TBL] [Abstract][Full Text] [Related]
17. B cells in multiple sclerosis therapy-A comprehensive review.
Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
[TBL] [Abstract][Full Text] [Related]
18. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
[TBL] [Abstract][Full Text] [Related]
19. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
Delgado SR; Faissner S; Linker RA; Rammohan K
J Neurol; 2024 Apr; 271(4):1515-1535. PubMed ID: 37906325
[TBL] [Abstract][Full Text] [Related]
20. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management.
Alvarez E; Longbrake EE; Rammohan KW; Stankiewicz J; Hersh CM
Mult Scler Relat Disord; 2023 Nov; 79():105009. PubMed ID: 37783194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
